Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125FAK) in prostate carcinoma.

  title={Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125FAK) in prostate carcinoma.},
  author={M. Duncan and J. Harmon and L. Duncan},
  journal={The Journal of surgical research},
  volume={63 1},
UNLABELLED Jasplakinolide is a member of a new class of antitumor agents targeting the actin cytoskeleton with activity against prostate cancer. Focal adhesion kinase (FAK) is an actin-associated mediator of mitogenic peptides. We hypothesized that the neuropeptide bombesin would activate FAR in prostate carcinoma, and that disruption of the actin network would block FAK activation and inhibit cell growth. METHODS PC-3 human prostate carcinoma cells were exposed to 50-200 nM jasplakinolide… Expand
Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility
Characterization of the activities of actin-affecting drugs on tumor cell migration.
Cucurbitacin E targets proliferating endothelia.
Jasplakinolide: an actin-specific reagent that promotes actin polymerization.
  • A. Holzinger
  • Biology, Medicine
  • Methods in molecular biology
  • 2009
Clinical significance of FAK expression in human neoplasia.
Targeting actin remodeling profiles for the detection and management of urothelial cancers--a perspective for bladder cancer research.
  • J. Rao
  • Biology, Medicine
  • Frontiers in bioscience : a journal and virtual library
  • 2002
Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma